Stevanato Group S.p.A.
NYSE:STVNMedical - Instruments & Supplies
+$0.67 today
- Market cap
- $4.20B
- Beta
- 0.78
- P/E (TTM)
- 29.9
- EPS (TTM)
- $0.52
- Dividend yield
- 0.35%
Volume 0.61M
Average 0.52M
STVN Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Stevanato Group S.p.A.NYSE: STVN
Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026
Capital expenditures growth accelerates
Q2 FY2026 capital expenditures of €65.73M (cash outflow) rose 9.1% year over year, ahead of the -38.5% change in trailing-twelve-month capital expenditures. Sequentially, it fell 7.1% from the prior quarter. Over 3 fiscal years it compounded at +1.4% a year.
Context
- Capital expenditures amounted to 22.2% of revenue in FY2025, down 6.2 pp from a year earlier.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +9.1% holds above the trailing-twelve-month pace of -38.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
EUR · from the cash flow
- Latest · FY2025
- (253.35M) EUR
- Year-over-year change
- +19.2%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (253.35M) | +19.2% |
| FY2024 | 2024-12-31 | (313.57M) | +29.0% |
| FY2023 | 2023-12-31 | (441.93M) | -81.8% |
| FY2022 | 2022-12-31 | (243.13M) | -114.8% |
| FY2021 | 2021-12-31 | (113.18M) | — |
Capital Expenditures vs competitors
How STVN compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -38.5% is the 7th highest of 10, against a peer median of -9.4%.
- Capital expenditures amounts to 22.3% of revenue for STVN, versus a peer median of 1.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $318.06M USD | -9.4% | +25.9% | 6.0% | |
| LTM Jun 2026 | $273.09M USD | -0.6% | -5.0% | 6.9% | |
| LTM Jun 2026 | €272.65M EUR | -38.5% | +1.4% | 22.3% | |
| LTM Jun 2026 | $142.3M USD | +13.0% | -1.2% | 2.2% | |
| LTM Sep 2026 | $110.33M USD | +50.9% | +10.8% | 0.7% | |
| LTM Jun 2026 | $66.35M USD | +19.8% | +3.1% | 2.6% | |
| LTM Apr 2026 | $23.2M USD | -47.9% | -29.9% | 1.5% | |
| LTM Sep 2026 | $21.52M USD | -22.3% | +23.5% | 1.3% | |
| LTM Jun 2026 | $11.81M USD | -90.0% | +6.3% | 0.5% | |
| LTM Jun 2026 | $129K USD | -44.2% | -11.9% | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| Peer median (excluding STVN) | — | -9.4% | +3.1% | 1.5% | |
Competitors are the stored peer set for STVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 165.67M | 187.64M | 189.55M | 160.29M | 134.32M |
| Depreciation & Amortization | 56.38M | 64.82M | 78.48M | 80.65M | 88.57M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 |
| Change in Working Capital | (41.63M) | (117.74M) | (102.48M) | (17.41M) | 48.63M |
| Accounts Receivables | (54.77M) | (46.42M) | (93.86M) | (3.83M) | 855.83K |
| Inventory | (31.2M) | (107.37M) | (113.59M) | 12.31M | (39.82M) |
| Accounts Payables | 44.34M | 36.05M | 104.97M | (25.89M) | 87.59M |
| Other Working Capital | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | (47.09M) | (31.41M) | (60.34M) | (67.76M) | 3.27M |
| Operating Cash Flow | 133.34M | 103.31M | 105.21M | 155.78M | 274.79M |
| Capital Expenditures | (113.18M) | (243.13M) | (441.93M) | (313.57M) | (253.35M) |
| Acquisitions (Net) | 14.81M | 0 | (3.59M) | (175K) | 1.79M |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 773K | 31K | 0 | 0 | 241.09K |
| Other Investing Activities | (4.32M) | (7.95M) | 15.6M | (7.44M) | 0 |
| Investing Cash Flow | (96.43M) | (242.95M) | (421.22M) | (310.21M) | (262.15M) |
| Debt Repayment | (120.18M) | (31.04M) | 172.57M | 27.91M | 41.38M |
| Common Stock Issued | 380.09M | 0 | 0 | 169.77M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (11.2M) | (13.5M) | (14.29M) | (14.46M) | (14.16M) |
| Other Financing Activities | 6.13M | 0 | (250K) | 0 | (6.03M) |
| Financing Cash Flow | 254.85M | (44.54M) | 158.03M | 183.22M | 21.19M |
| Effect of Forex Changes | 3.68M | 1.88M | (1.16M) | (115K) | 10.11M |
| Net Change in Cash | 295.44M | (182.3M) | (159.14M) | 28.67M | 43.94M |
| Free Cash Flow | 20.16M | (139.82M) | (336.72M) | (157.8M) | 21.44M |
Stevanato Group S.p.A.
NYSE:STVN
Intrinsic Alpha fair value
Locked
Current Price
$15.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.